Is Race an Independent Prognostic Factor for Survival from Prostate Cancer?

Journal of the National Medical Association

Volumn 90, Issue SUPPL., 1998, Pages

  Roach III, Mack ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b 20 Castleton Place ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHNOLOGY; HUMAN; MALE; MORTALITY; NEGRO; PROGNOSIS; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SURVIVAL RATE; UNITED STATES;

EID: 0346836939     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Roach M, Cirricone C, Budman D, et al. Race and survival from breast cancer: based on Cancer and Leukemia Group B Trial 8541. Cancer J Sci Am. 1997;3:107-112.
2. Roach M III, Alexander M. The prognostic significance of race and survival from breast cancer: a model for assessing the reliability of reported survival differences. J Natl Med Assoc. 1995;87:214-219.
3. Silverberg E. Cancer statistics. Cancer Statistics. 1980;30:23.
4. Walker AR, Walker BF, Segal I. Cancer patterns in three African populations compared with the United States black population. Eur J Cancer Prev. 1993;2:313-320.
5. Cavalli-Sforza LL. Genes, peoples and languages. Sci Am. 1991;11:104-110.
6. Ingles SA, Haile RW, Henderson BE, et al. Strength of linkage disequilibrium between two vitamin D receptor markers in five ethnic groups: implications for association studies. Cancer Epidemiol Biomarkers Prev. 1997;6:93-98.
7. Doll JA, Suarez BK, Donis-Keller H. Association between prostate cancer in black Americans and an allele of the PADPRP pseudogene locus on chromosome 13. Am J Hum Genet. 1996;58:425-428. Letter.
8. Corder EH, Friedman GD, Vogelman JH, et al. Seasonal variation in vitamin D, vitamin D-binding protein, and dehy droepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev. 1995;4:655-659.
9. Rodriguez C, Tatham LM, Thun MJ, et al. Smoking and fatal prostate cancer in a large cohort of adult men. Am J Epidemiol 1997;145:466-475.
10. Dale W, Vijayakumar S, Lawlor EF, et al. Prostate cancer, race, and socioeconomic status: inadequate adjustment for social factors in assessing racial differences. Prostate. 1996;29:271-281.
11. Coughlin SS, Neaton JD, Sengupta A. Cigarette smoking as a predictor of death from prostate cancer in 348,874 men screened for the Multiple Risk Factor Intervention Trial. Am J Epidemiol. 1996;143:1002-1006.
12. Godley PA, Campbell MK, Miller C, et al. Correlation between biomarkers of omega-3 fatty acid consumption and questionnaire data in African American and caucasian United States males with and without prostatic carcinoma. Cancer Epidemiol Biomarkers Prev. 1996;5:115-119.
13. Reichardt JK, Makridakis N, Henderson BE, et al. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 1995;55:3973-3975.
14. Monroe KR, Yu MC, Kolonel LN, et al. Evidence of an X-linked or recessive genetic component to prostate cancer risk. Nat Med. 1995;1:827-829.
15. Demark-Wahnefried W, Strigo T, Catoe K, et al. Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening. Urology. 1995;46:346-351.
16. Taylor JA, Hirvonen A, Watson M, et al. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res. 1996;56:4108-4110.
17. Hiatt RA, Armstrong MA, Klatsky AL, et al. Alcohol consumption, smoking, and other risk factors and prostate cancer in a large health plan cohort in California (United States). Cancer Causes Control. 1994;5:66-72.
18. Hsing AW, McLaughlin JK, Schuman LM, et al. Diet, tobacco use, and fatal prostate cancer: results from the Lutheran Brotherhood cohort study. Cancer Res. 1990;50:6836-6840.
19. Hsing AW, Comstock GW. Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer. Cancer Epidemiol Biomarkers Prev. 1993;2:27-32.
20. Hiatt RA, Ordonez JD. Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample [published erratum appears in Cancer Epidemiol Biomarkers Prev. 1994;3:523]. Cancer Epidemiol Biomarkers Prev. 1994;3:439-443.
21. Braun MM, Helzlsouer KJ, Hollis BW, et al. Prostate cancer and prediagnostic levels of serum vitamin D metabolites (Maryland, United States). Cancer Causes Control 1995;6:235-239.
22. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol. 1993;1j50:797-802.
23. Corder EH, Guess HA, Hulka BS, et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev. 1993;2:467-472.
24. Rotimi C, Austin H, Delzell E, et al. Retrospective follow-up study of foundry and engine plant workers. Am J Ind Med. 1993;24:485-498.
25. Reichman ME, Hayes RB, Ziegler RG, et al. Serum vitamin A and subsequent development of prostate cancer in the first National Health and Nutrition Examination Survey epidemiologic follow-up study. Cancer Res. 1990;50:2311-2315.
26. Wu AH, Whittemore AS, Kolonel LN, et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev. 1995;4:735-741.
27. Steele R, Lees REM, Kraus AS, et al. Sexual factors in epidemiology of cancer of the prostate. J Chron Dis. 1971;24:29-37.
28. Lyn D, Cherney BW, Lalande M, et al. A duplicated region is responsible for the poly(ADP-ribose) polymerase polymorphism, on chromosome 13, associated with a predisposition to cancer. Am J Hum Genet. 1993;52:124-134.
29. Matzkin H, Soloway MS. Cigarette smoking: a review of possible associations with benign prostatic hyperplasia and prostate cancer. Prostate. 1993;22:277-290.
30. Franklin JH, Moss AA. From Slavery to Freedom. 7th ed. New York, NY: McGraw-Hill; 1994.
31. Jones JH. Bad blood. In: Press F, ed. The Tuskegee Syphilis Experiment: A Tragedy of Race and Medicine. New York, NY: Macmillan Publishing Co Inc; 1981.
32. Crawford ED, Blumenstein BA, Goodman PJ, et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer. 1990;66:1039-1044.
33. Roach M, Krall J, Perez CA, et al. The prognostic significance of race and survival from prostate cancer based on patients irradiated on Radiation Therapy Oncology Group Protocols (1976-1985). Int J Radiat Oncol Biol Phys. 1992;24:441-449.
34. Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology. 1995;46:220-226.
35. Smith DC, Trump DL, Vogelzang NJ, et al. The effect of African American race on response and survival in phase II trials of patients with hormone-refractory prostate cancer. Proceedings of ASCO. 1996;15(suppl):242.
36. Kennealey GT, Vogelzang NJ, Soloway MS, et al. Analysis of time to treatment failure by extent of disease and race in a randomized, multicenter trial comparing Casodex (bicalutamide) (C) with Eulexin (flutamide) (E), each combined with luteinizing hormone releasing hormone. Proceedings of ASCO. 1996;15:251.
37. Moul JW, Douglas TH, McCarthy WF, et al. Black race is an adverse prognostic factor for prostate cancer recurrence following radical prostatectomy in an equal access health care setting. J Urol. 1996;155:1667-1673.
38. Perez CA, Garcia D, Simpson JR, et al. Factors influencing outcome of definitive radiotherapy for localized carcinoma of the prostate. Radiother Oncol. 1989; 16:1-21.
39. Powell IJ, Schwartz K, Hussain M. Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans Affairs system. Urology. 1995;46:825-830.
40. Kim JA, Kuban DA, El-Mahdi EM, et al. Carcinoma of the prostate: race as a prognostic indicator in definitive radiation therapy. Radiology. 1995;194:545-549.
41. Weinberger M, Williams B, Davis T, et al. Low literacy scores predict advanced stage prostate cancer presentation in African-American men. Am Urol Assoc. 1996;155:606A.
42. Nautiyal J, Vaida F, Awan A, et al. The impact of race on biochemical outcome in patients receiving irradiation for prostate cancer. Int J Radiat Biol Phys. 1996;36:305.
43. Hart KB, Porter AT, Reddy S, et al. The Relationship of race to the presentation and natural history of prostate cancer. Proceedings of ASCO. 1996;15:247.
44. Austin J-P, Aziz H, Potters L, et al. Diminished survival of young blacks with adenocarcinoma of the prostate. Am J Clin Oncol. 1990;13:465-469.
45. Aziz H, Rotman M, Thelmo W, et al. Radiation-treated carcinoma of the prostate. Am J Clin Oncol. 1988;11:166-171.
46. Dayal HH, Chiu C. Factors associated with racial differences in survival for prostatic carcinoma. J Chron Dis. 1982;35:553-560.
47. Epstein JI, Paull G, Eggleston JC, et al. Prognosis of untreated stage A1 prostatic carcinoma: a study of 94 cases with extended follow-up. J Urol. 1986;136:837-839.
48. Fowler JE Jr, Terrell F. Survival in blacks and whites after treatment for localized prostate cancer. J Urol. 1996;156:133-136.
49. Hussain F, Aziz H, Macchia R, et al. High grade adenocarcinoma of prostate in smokers of ethnic minority groups and Caribbean island immigrants. Int J Radiat Biol. 1992;24:451-461.
50. Lawton CA, Cantrell JE, Derus SW, et al. Prostate cancer: are racial differences in clinical stage and survival explained by differences in symptoms? Radiology. 1994;192:37-40.
51. Levine RL, Wilchinsky M. Adenocarcinoma of the prostate: a comparison of the disease in blacks versus whites. J Urol. 1979;121:761-762.
52. Austin J-P, Convery K. Age-race interaction in prostatic adenocarcinoma treated with external beam irradiation. Am J Clin Oncol. 1993;16:140-145.
53. Mettlin C, Murphy GP, Menck H. Trends in treatment of localized prostate cancer by radical prostatectomy. observations from the Commission on Cancer National Cancer Database, 1985-1990. Urology. 1994;43:488-492.
54. Murphy GP. Prostate cancer today. Urology. 1981;17:1-3.
55. Natarajan N, Murphy GP, Mettlin C. Prostate cancer in blacks: an update from the American College of Surgeons' patterns of care studies. J Surg Oncol. 1989;40:232-236.
56. Optenberg SA, Thompson IM, Friedrichs P, et al. Race, treatment, and long-term survival from prostate cancer in an equal-access medical care delivery system. JAMA. 1995;74:1599-1605.
57. Page WF, Kuntz AJ. Racial and socioeconomic factors in cancer survival. Cancer. 1980;45:1029-1040.
58. Pienta KJ, Demers R, Hoff M, et al. Effect of age and race on the survival of men with prostate cancer in the metropolitan Detroit tricounty area, 1973 to 1987. Urology. 1995;45:93-102.